SERTAD4 Inhibitors
Chemical inhibitors of SERTAD4 encompass a range of compounds known for their ability to disrupt the cell cycle by targeting cyclin-dependent kinases (CDKs), enzymes which are integral for the progression and regulation of the cell cycle. Palbociclib and Ribociclib, for instance, are selective inhibitors of CDK4/6. By inhibiting these kinases, they induce a G1 phase arrest, effectively preventing the progression to the S phase where SERTAD4 is most active. This inhibition obstructs SERTAD4's functional engagement in cell cycle regulation at a critical juncture, thereby curtailing its activity. Similarly, Abemaciclib targets the same kinases, resulting in a comparable functional inhibition of SERTAD4 by halting the cell cycle before SERTAD4's phase of activity.
Other inhibitors, such as Olomoucine, Roscovitine (Seliciclib), and Purvalanol A, take a slightly broader approach by affecting CDK1, CDK2, and CDK3, kinases that are also involved in cell cycle regulation but at different checkpoints. Olomoucine, specifically, targets early stages of cell division, leading to an arrest that precludes SERTAD4 from acting during the G1/S transition. Roscovitine and Purvalanol A extend this inhibition to other phases, encompassing CDK7 and CDK9 as well, further ensuring that SERTAD4 is unable to contribute to cell cycle progression at multiple points. Milciclib, while also affecting CDKs, extends its reach to tropomyosin receptor kinases (TRKs), adding another layer of regulation that could intersect with SERTAD4's role. The compounds Flavopiridol, Dinaciclib, and AT7519 exert their inhibitory effects on a range of CDKs that are critical for the cell cycle, thereby disrupting the cycle at multiple points and ensuring that SERTAD4 does not find a conducive environment for its activity. AZD5438 also targets CDK1, CDK2, and CDK9, which by their inhibition, arrest the cell cycle at various stages, consequently inhibiting the functional role of SERTAD4 throughout cell cycle progression.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib inhibits CDK4/6, which are crucial for cell cycle progression. Inhibition of CDK4/6 can lead to a G1 phase arrest. As SERTAD4 is involved in cell cycle regulation and is known to peak during the G1/S transition, inhibiting CDK4/6 would impede the cell cycle progression, thereby functionally inhibiting the activity of SERTAD4 by preventing its associated cell cycle phase from being reached. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Olomoucine is a selective inhibitor of CDKs, particularly CDK1, CDK2, and CDK3. By inhibiting these CDKs, the cell cycle is arrested, and the environment in which SERTAD4 operates is compromised. Since the role of SERTAD4 is associated with the regulation of the cell cycle, olomoucine's ability to arrest the cell cycle would functionally inhibit SERTAD4 by not allowing the cell cycle to progress to the stage where SERTAD4 is active. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $92.00 $260.00 | 42 | |
Roscovitine, also known as Seliciclib, is a potent inhibitor of CDK2, CDK7, and CDK9. SERTAD4, being involved in the regulation of the cell cycle, would be functionally inhibited by roscovitine since its action on CDKs would arrest the cell cycle, hence preventing SERTAD4 from exerting its role during the cell cycle progression. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $71.00 $291.00 | 4 | |
Purvalanol A is an inhibitor of CDK1, CDK2, and CDK5. By inhibiting these kinases, purvalanol A can arrest the cell cycle, thus functionally inhibiting SERTAD4 by impeding the progression to the cell cycle stages where SERTAD4 is active. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $242.00 $871.00 | 1 | |
Dinaciclib strongly inhibits CDK1, CDK2, CDK5, and CDK9. SERTAD4, which operates within the cell cycle regulation, would be functionally inhibited by dinaciclib because its inhibition of these CDKs would lead to cell cycle arrest, thereby preventing SERTAD4 activity. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $254.00 | 41 | |
Flavopiridol inhibits CDKs necessary for cell cycle progression, including CDK1, CDK2, CDK4, and CDK6. As SERTAD4 is involved in cell cycle progression, flavopiridol's inhibition of these CDKs would functionally inhibit SERTAD4 by halting the cell cycle before SERTAD4's functional phase. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Ribociclib selectively inhibits CDK4/6, which are essential for G1-S phase transition. Inhibition of these kinases functionally inhibits SERTAD4 by preventing the cell cycle from reaching the phase where SERTAD4 is active, thereby limiting its functional role. | ||||||
PHA-848125 | 802539-81-7 | sc-364581 sc-364581A | 5 mg 10 mg | $304.00 $555.00 | ||
Milciclib targets multiple CDKs and tropomyosin receptor kinases (TRKs). By inhibiting these kinases, milciclib can arrest the cell cycle and impede the signaling pathways that SERTAD4 is part of, leading to functional inhibition of SERTAD4. | ||||||
Abemaciclib | 1231929-97-7 | sc-507342 | 10 mg | $110.00 | ||
Abemaciclib is an inhibitor of CDK4 and CDK6. This compound would functionally inhibit SERTAD4 by preventing the cell cycle from advancing to the G1/S phase where SERTAD4 is implicated, thereby inhibiting its role in cell cycle regulation. | ||||||
AT7519 | 844442-38-2 | sc-364416 sc-364416A sc-364416B sc-364416C | 5 mg 10 mg 100 mg 1 g | $207.00 $246.00 $1025.00 $3065.00 | 1 | |
AT7519 inhibits multiple CDKs, including CDK1, CDK2, CDK4, CDK5, and CDK9. This broad inhibition of CDKs would lead to a cell cycle arrest, functionally inhibiting SERTAD4 by preventing the cell cycle phase transitions that are necessary for SERTAD4's activity. | ||||||